Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.63 |
| ▸ | PPARG | P37231 | 8/20 | 0.63 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821539 | 1.00 | PPARA (0.63) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL28126437 | 0.87 | PPARA (0.61) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL28126434 | 0.87 | PPARA (0.61) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL29548389 | 0.87 | PPARA (0.61) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL7283699 | 0.87 | PPARA (0.55) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL16648476 | 0.86 | ADRB2 (0.56) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL7352216 | 0.86 | ADRB2 (0.56) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL7381690 | 0.86 | ADRB2 (0.56) | PPARAPPARGPPARDADRB2ADRB1 | |
| SCHEMBL5970314 | 0.84 | TDP1 (0.52) | PPARAPPARGPPARDACEIDO1 | |
| SCHEMBL28905329 | 0.83 | PPARA (0.59) | PPARAPPARGPPARDACEIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250226-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORP (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12319643-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2025-06-03 | — | — | US | disclosed |
| US-20220242820-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2022-08-04 | — | — | US | disclosed |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2022-07-12 | — | — | US | disclosed |
| EP-3313449-B1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| EP-3686184-A2 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20190127318-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| US-10167253-B2 | Ionizable compounds and compositions and uses thereof | NITTO DENKO CORPORATION (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-3313449-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Nitto Denko Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210190-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376229-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NITTO DENKO CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242820-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, RNASE1, RNMT | PPARA 2556/4885PPARG 3580/4885PPARD 4397/4885 |
| US-20250250226-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, RNASE1, RNMT | PPARA 2556/4885PPARG 3580/4885PPARD 4397/4885 |
| US-10167253-B2 | Ionizable compounds and compositions and uses thereof | NCL, CHMP4B, RNASE1 | PPARA 3220/4885PPARG 4244/4885PPARD 4579/4885 |
| US-20160376229-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, CHMP4B, RNASE1 | PPARA 3220/4885PPARG 4244/4885PPARD 4579/4885 |
| US-11384051-B2 | Ionizable compounds and compositions and uses thereof | NCL, CHMP4B, RNASE1 | PPARA 3220/4885PPARG 4244/4885PPARD 4579/4885 |
| US-20190127318-A1 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | NCL, CHMP4B, RNASE1 | PPARA 3220/4885PPARG 4244/4885PPARD 4579/4885 |
| US-12319643-B2 | Ionizable compounds and compositions and uses thereof | NCL, RNASE1, RNMT | PPARA 2556/4885PPARG 3580/4885PPARD 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.